GLP-1 Agonist Therapy Center

Early intervention in treating diabetes has shown long term benefits, follow-up data for both old and new studies show.

Study focuses on differences in clinical outcomes between initiating glucagon-like peptide-1 receptor agonist (GLP-1 RAs) vs. insulin treatment in patients with type 2 treated with oral glucose-lowering medications (OGLM).

What benefits can lixisenatide provide when added to basal insulin regimen?

Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?

A phase 2 randomized controlled trial demonstrated clinically significant changes in glycemic control.

Female 43 years of age. Type 1 diabetes/insulin resistant, hyperglycemia, increasing insulin to manage glucose, but not covering well. Increasing appetite and gaining weight. GLP-1 (Victoza) added at 1/2 recommended start dose for people who have type 2 diabetes, which is 0.6mg, so patient started at 0.3mg daily. Patient started having hypoglycemic reactions, most often postprandially and nocturnally.

Cardioprotective effects of the drug are focus of research.

Does insulin cause more deaths and cardiovascular outcomes than GLP-1 agonist receptors?

LEADER showed liraglutide reduces risk of cardiovascular death, but latest study shows no benefit to high-risk patients.

63-year-old male, moderate cognitive impairment and lives alone. Patient lost a significant amount of weight, frequent symptomatic hypoglycemia, including light-headedness and dizziness, requiring lowering and stopping some of his glucose lowering medications. GLP-1 was stopped and his glucose levels were in normal range. We were very clear that he should not resume his GLP-1 until we saw him again.